Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα InhibitionMei Li(Soochow University), Yanhua Fan(Southwest University)International Journal of Molecular SciencesApril 6, 202310.3390/ijms24076851Cited by 7SaveCiteExport RISWatch citationsRelated PapersDiscovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia|Nature Cancer|2021|279Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer|Cancers|2019|20Glaucocalyxin A suppresses multiple myeloma progression in vitro and in vivo through inhibiting the activation of STAT3 signaling pathway|Cancer Cell International|2021|10